Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company. It focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket Pharmaceuticals Inc., formerly known as Inotek Pharmaceuticals Corporation, is based in LEXINGTON, United States.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-258.75M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.00 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -65.11% |
| Return on Assets (Trailing 12 Months) | -55.99% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.39 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.39 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.05 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.28 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.59 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.73 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.51 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 107.90M |
| Free Float | 81.19M |
| Market Capitalization | $358.24M |
| Average Volume (Last 20 Days) | 5.84M |
| Beta (Past 60 Months) | 0.65 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 24.76% |
| Percentage Held By Institutions (Latest 13F Reports) | 98.39% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |